{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-014382","form_type":"8-K","ticker":"PBYI","cik":"0001401667","company_name":"PUMA BIOTECHNOLOGY, INC.","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.251470+00:00","generated_at":"2026-06-03T00:14:54.471095+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Puma Biotech Q1 net loss $4.8M vs prior year net income; NERLYNX revenue down 14%","bullets":["Net product revenue $40.3M (Q1 2023: $46.8M); total revenue $43.8M including $3.5M royalties.","GAAP net loss $0.10/shr; non-GAAP adjusted net loss $0.05/shr vs adjusted net income $0.09/shr in Q1 2023.","Cash, cash equivalents and marketable securities $107.2M at March 31, 2024; operating cash flow $11.3M.","Q2 2024 guidance: net product revenue $43-45M, net loss $(6)-(9)M; FY2024: product revenue $183-190M, net income $12-15M.","Initiated alisertib Phase II trial in small cell lung cancer (ALISCA-Lung1); key milestones through Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-014382","json":"https://secwatch.observer/filing/0001437749-24-014382.json","markdown":"https://secwatch.observer/filing/0001437749-24-014382.md","text":"https://secwatch.observer/filing/0001437749-24-014382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401667/000143774924014382/0001437749-24-014382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401667/000143774924014382/pbyi20240430_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:14:54.471095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d876d8f96cf3f169356868ec62f004afa62daaa6","claim":"PUMA BIOTECHNOLOGY, INC. reported the first quarter ended March 31, 2024 results: revenue $43.8 million, net income net loss of $4.8 million, EPS $0.10 per basic and diluted share.","evidence_excerpt":"sales of NERLYNX, Puma’s first commercial product, license revenue from Puma’s sub-licensees and royalty revenue. For the first quarter ended March 31, 2024, total revenue was $43.8 million, of which $40.3 million was net product revenue and $3.5 million was royalty revenue. This compares to total revenue of $52.8 million in the first quarter of 2023, of which $46.8","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401667/000143774924014382/0001437749-24-014382-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$43.8 million"},{"label":"Net income","value":"net loss of $4.8 million"},{"label":"EPS","value":"$0.10 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}